Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database.
Publication Title
Experimental biology and medicine (Maywood, N.J.)
Document Type
Article
Publication Date
10-5-2020
Keywords
BRAF; Cancer; biomarkers; colon; kinase; melanoma; genomics
Abstract
IMPACT STATEMENT: These data represent the largest aggregation of BRAF mutations within a single clinical database to our knowledge. The relative proportions of both BRAF V600 mutations and non-V600 mutations are informative in all cancers and by malignancy, and can serve as a definitive gold-standard for BRAF mutation cancer incidence by malignancy. The rate of BRAF mutation in human cancer in a real-world large database is lower than previously reported likely representing testing more broadly across tumor types. The relative percentages of Class II and Class III BRAF mutations are higher than previously reported, representing almost 35% of BRAF mutations in cancer. These findings provide support for the development of effective treatments for non-V600 BRAF mutations in cancer.
Clinical Institute
Cancer
Specialty/Research Institute
Oncology
